Phosphate - The silent stealthy cardiorenal culprit in all stages of chronic kidney disease: A systematic review

Blood Purification

Volumn 27, Issue 2, 2009, Pages 220-230

  Kanbay, Mehmet ^a,d   Goldsmith, David ^b   Akcay, Ali ^a   Covic, Adrian ^c  

^a FATIH UNIVERSITY   (Turkey)

^b GUY S HOSPITAL   (United Kingdom)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^d NONE   (Turkey)

Author keywords

Cardiac mortality; Cardiovascular disease; Hyperphosphatemia; Kidney disease; Phosphate

Indexed keywords

PHOSPHATE;

ADVERSE OUTCOME; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DATA BASE; DIALYSIS; DISEASE COURSE; HUMAN; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CALCIUM; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 58749105348     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197562     Document Type: Review

References (58)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994;9:1136-1142.
2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663.
3. Vanholder R, Meert N, Schepers E, Glorieux G: Uremic toxins: do we know enough to explain uremia? Blood Purif 2008;26:77-81.
4. Covic A, Gusbeth-Tatomir P, Goldsmith D: Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol Dial Transplant 2008;23:56-61.
5. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-S119.
6. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35(4 suppl 1):S117-S131.
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
8. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
9. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
12. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-779.
13. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187.
14. Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB; NECOSAD study group: Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline. Blood Purif 2008;26:231-237.
15. Matsubara K, Suliman ME, Qureshi AR, Axelsson J, Martola L, Heimbürger O, Barany P, Stenvinkel P, Lindholm B: Bone mineral density in end-stage renal disease patients: association with wasting, cardiovascular disease and mortality. Blood Purif 2008;26:284-290.
16. Covic A, Gusbeth-Tatomir P, Goldsmith DJ: Vascular calcification - a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity. Semin Dial 2007;20:158-169.
17. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ: The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008;51:212-223.
18. Hayden JA, Côté P, Bombardier C: Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-437.
19. Narang R, Ridout D, Nonis C, Kooner JS: Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol 1997;60:73-79.
20. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-112.
21. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol and Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633.
22. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
23. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-885.
24. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW, Vaccarino V, Raggi P: Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008;199:424-431.
25. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008;73:1296-1302.
26. Kanbay M, Isik B, Akcay A, Ozkara A, Karakurt F, Turgut F, Alkan R, Uz E, Bavbek N, Yigitoglu R, Covic A: Relation between serum calcium, phosphate, parathyroid hormone and 'nondipper' circadian blood pressure variability profile in patients with normal renal function. Am J Nephrol 2007;27:516-521.
27. Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005;46:455-463.
28. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW; PREPARE study group: High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007;22:2909-2916.
29. Hsu CY, Chertow GM: Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 2002;17:1419-1425.
30. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-831.
31. Hruska K, Slatopolsky E: Disorders of phosphorus, calcium, and magnesium; in Schrier R, Gottschalk C (eds): Diseases of the Kidney. London, Little, Brown, 1996, vol 3, pp 2477-2526.
32. Klahr S: The Kidney and Body Fluids in Health and Disease. New York, Plenum, 1983.
33. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977-981.
34. Chen NX, O'Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
35. Moe SM, Chen NX: Mechanisms of Vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213-216.
36. Giachelli CM: Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14(9 suppl 4):S300-S304.
37. Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V: Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-2244.
38. Amann K, Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003;63:1296-1301.
39. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-1819.
40. Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Rudikoff S, Jilka RL, Manolagas SC, Insogna K: A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 1999;140:4683-4690.
41. Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K: Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001;280:E405-E412.
42. Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
43. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y: Klotho , a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-2403.
44. Shimada T, Kakitani M, Yamazaki Y, et al: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-568.
45. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, Takeshige K, Kamiya T: The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001;131:3182-3188.
46. Taketani Y, Shuto E, Arai H, Nishida Y, Tanaka R, Uebanso T, Yamamoto H, Yamanaka-Okumura H, Takeda E: Advantage of a low glycemic index and low phosphate diet on diabetic nephropathy and aging-related diseases. J Med Invest 2007;54:359-365.
47. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005;280:38029-38034.
48. Chan CT, Wells H, Kramsch DM: Suppression of calcific fibrous-fatty plaque formation in rabbits by agents not affecting elevated serum cholesterol levels. The effect of thiophene compounds. Circ Res 1978;43:115-125.
49. Portale AA, Halloran BP, Morris RC Jr: Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989;83:1494-1499.
50. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990;19:559-563.
51. Brunvand L, Hågå P, Tangsrud SE, Haug E: Congestive heart failure caused by vitamin D deficiency? Acta Paediatr 1995;84:106-108.
52. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997;96:1755-1760.
53. Hedbäck G, Odén A: Increased risk of death from primary hyperparathyroidism - an update. Eur J Clin Invest 1998;28:271-276.
54. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006;70:2141-2147.
55. Koizumi T, Murakami K, Nakayama H, Kuwahara T, Yoshinari Ohnishi: Role of dietary phosphorus in the progression of renal failure. Biochem Biophys Res Commun 2002;295:917-921.
56. Lau K: Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int 1989;36:918-937.
57. Loghman-Adham M: Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993;122:16-26.
58. Maschio G, Oldrizzi L, Tessitore N, D'Angelo A, Valvo E, Lupo A, Loschiavo C, Fabris A, Gammaro L, Rugiu C, et al: Early dietary protein and phosphorus restriction is effective in delaying progression of chronic renal failure. Kidney Int Suppl 1983;16:S273-S277.